Genmab — September 2023

[Riis7]

Godmorgen ligner endnu en rød dag desværre ,
bjørnen er kommet

[JKY_VH]

Så må skyde den Riis7 og få solgt skindet;-)

[StockBull]

Ja en korrektion ned til test af SP500, 200 dages snit pt. beliggende i ca. 4.185 (måske lidt under) er nok ikke utænkelig på den helt korte bane

[Riis7]

Jeg har gemt mig og gået cash med rente;-)

[Riis7]

https://borsen.dk/nyheder/markedsberetninger/vigtig-rente-rammer-hojeste-niveau-siden-2007-saadan-bliver-handelsdagen?b_source=borsen&b_medium=row_0&b_campaign=list_5

[E_L]

@gentogen we should see some headline results within the next few months. The OLE looks promising?

[gentogen]

Yes.It is also an offer to the previous placebo patients to receive Lu AF82422. No reason to do so, if there were no promising effect of some degree

[E_L]

Well, that i am actually not sure about; i initially thought the same, but when you look at the 2 arms, it seems the OLE is only offered in the arm that receives Lu AF82422?

[gentogen]

You could be right. Hard to tell from the wording. In any case, I see it as somewhat positive news

[Vitus]

Dejligt med en sjat Novo og Genmab i depoterne i dag

[MAXIME]

Hvis du ligefrem synes Genmab præsterer på samme højde som Novo i depoterne, så du da være ny…. Genmab har ikke rykket sig de sidste 2 år!!!

[gdn55]

Han skriver idag

[Pensionisten]

To sjæle -een tanke. Var

[Pensionisten]

Var selv på vej med kommentaren @gdn

[Vitus]

Ja, du må lige læse hele teksten Maxime

[StockBull]

The Trading & Investment Specialist

Saxo Bank A/S is a fully licensed and regulated Danish bank with an online trading platform that empowers you to invest across global financial markets.

(www.saxotrader.com)

[StockBull]

The Trading & Investment Specialist

Saxo Bank A/S is a fully licensed and regulated Danish bank with an online trading platform that empowers you to invest across global financial markets.

(www.saxotrader.com)

[E_L]

Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data https://www.dovepress.com/therapeutic-potential-of-tisotumab-vedotin-in-the-treatment-of-recurre-peer-reviewed-fulltext-article-CMAR

[E_L]

Second-Line Tisotumab Vedotin Shows Durability in Cervical Cancer https://www.targetedonc.com/view/second-line-tisotumab-vedotin-shows-durability-in-cervical-cancer

[E_L]

20 November 2023 at Panum, UCPH, Keynote speaker Jan G. J. van de Winkel https://bridge.ku.dk/alumni-network/alumni-event/ may be of interest to some locals